• Je něco špatně v tomto záznamu ?

Enrichment of circulating trophoblasts from maternal blood using filtration-based Metacell® technology

J. Weymaere, AS. Vander Plaetsen, Y. Van Den Branden, E. Pospisilova, O. Tytgat, D. Deforce, F. Van Nieuwerburgh

. 2022 ; 17 (7) : e0271226. [pub] 20220714

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22025222

In a cell-based non-invasive prenatal test (cbNIPT), intact circulating trophoblasts (CTs) are isolated from maternal blood for subsequent genetic analysis. Enrichment of these CTs from maternal blood is the most challenging step in the cbNIPT workflow. This study aims to assess the suitability of the filtration-based Metacell® technology to enrich CTs from maternal blood at week 10 to 13 of gestation. The Metacell® technology is a novel size-based enrichment technology that combines blood filtration through 8 μm pores with an in vitro culture method. Three protocols were evaluated. First, 8 mL or 16 mL of maternal blood was filtered and subsequently cultured in vitro on the separation membrane for 3 days in RPMI 1640. In addition, 16 mL of maternal blood was filtered, and immediately processed without further culturing. Y-chromosome-specific qPCR or STR analysis was performed to evaluate the enrichment of CTs. A total of 44 samples from pregnant women, out of which 26 were carrying a male fetus, were processed. Although five enriched male fetus samples show detectable male DNA quantities, it cannot be excluded that the obtained positive signal is caused by cell-free fetal DNA sticking to the Metacell® separation membrane. In conclusion, the Metacell® technology, tested as described, is not suitable for consistent enrichment of CTs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025222
003      
CZ-PrNML
005      
20221031101345.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0271226 $2 doi
035    __
$a (PubMed)35834570
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Weymaere, Jana $u Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium $1 https://orcid.org/0000000282131973
245    10
$a Enrichment of circulating trophoblasts from maternal blood using filtration-based Metacell® technology / $c J. Weymaere, AS. Vander Plaetsen, Y. Van Den Branden, E. Pospisilova, O. Tytgat, D. Deforce, F. Van Nieuwerburgh
520    9_
$a In a cell-based non-invasive prenatal test (cbNIPT), intact circulating trophoblasts (CTs) are isolated from maternal blood for subsequent genetic analysis. Enrichment of these CTs from maternal blood is the most challenging step in the cbNIPT workflow. This study aims to assess the suitability of the filtration-based Metacell® technology to enrich CTs from maternal blood at week 10 to 13 of gestation. The Metacell® technology is a novel size-based enrichment technology that combines blood filtration through 8 μm pores with an in vitro culture method. Three protocols were evaluated. First, 8 mL or 16 mL of maternal blood was filtered and subsequently cultured in vitro on the separation membrane for 3 days in RPMI 1640. In addition, 16 mL of maternal blood was filtered, and immediately processed without further culturing. Y-chromosome-specific qPCR or STR analysis was performed to evaluate the enrichment of CTs. A total of 44 samples from pregnant women, out of which 26 were carrying a male fetus, were processed. Although five enriched male fetus samples show detectable male DNA quantities, it cannot be excluded that the obtained positive signal is caused by cell-free fetal DNA sticking to the Metacell® separation membrane. In conclusion, the Metacell® technology, tested as described, is not suitable for consistent enrichment of CTs.
650    _2
$a DNA $7 D004247
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a plod $7 D005333
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a těhotenství $7 D011247
650    12
$a prenatální diagnóza $x metody $7 D011296
650    _2
$a technologie $7 D013672
650    12
$a trofoblasty $7 D014327
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vander Plaetsen, Ann-Sophie $u Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium
700    1_
$a Van Den Branden, Yasmine $u Obstetrics and gynecology, Ghent University Hospital, Ghent, Belgium
700    1_
$a Pospisilova, Eliska $u Faculty Hospital Královské Vinohrady, Laboratory Diagnostics, Prague, Czech Republic
700    1_
$a Tytgat, Olivier $u Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium $1 https://orcid.org/0000000217885963
700    1_
$a Deforce, Dieter $u Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium $1 https://orcid.org/000000020635661X
700    1_
$a Van Nieuwerburgh, Filip $u Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium $1 https://orcid.org/0000000188155485
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 17, č. 7 (2022), s. e0271226
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35834570 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031101343 $b ABA008
999    __
$a ok $b bmc $g 1854765 $s 1176512
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 17 $c 7 $d e0271226 $e 20220714 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace